Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression

BACKGROUND: Recent clinical trials on ovarian cancer with mifepristone (MF) have failed, despite in vitro findings on its strong progesterone (P4) antagonist function. METHODS: Ovarian cancer human and murine cell lines, cultured high-grade human primary epithelial ovarian cancer (HG-hOEC) cells and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ponikwicka-Tyszko, Donata, Chrusciel, Marcin, Stelmaszewska, Joanna, Bernaczyk, Piotr, Chrusciel, Paulina, Sztachelska, Maria, Scheinin, Mika, Bidzinski, Mariusz, Szamatowicz, Jacek, Huhtaniemi, Ilpo T., Wolczynski, Slawomir, Rahman, Nafis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796594/
https://www.ncbi.nlm.nih.gov/pubmed/31466918
http://dx.doi.org/10.1016/j.ebiom.2019.08.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796594/
https://www.ncbi.nlm.nih.gov/pubmed/31466918
http://dx.doi.org/10.1016/j.ebiom.2019.08.035

Ejemplares similares